Thus, the pathophysiological pathways of neurodegenerative diseases and the two diseases associated with VLGR1 defects, Usher syndrome type 2 and childhood absence epilepsy [4,6,7], may open the avenue for common therapeutic targets and therapy options. This evidence concerns the gene ADGRV1 and Usher syndrome type 2.